Pasithea Therapeutics (KTTA) Expected to Announce Quarterly Earnings on Monday

Pasithea Therapeutics (NASDAQ:KTTA) is projected to announce its results before the market opens on Monday, March 23rd. Analysts expect the company to announce earnings of ($0.18) per share for the quarter.

Pasithea Therapeutics Trading Down 0.9%

Shares of KTTA stock opened at $0.82 on Monday. The stock has a market cap of $18.93 million, a P/E ratio of -0.16 and a beta of 0.20. Pasithea Therapeutics has a 1 year low of $0.28 and a 1 year high of $3.79. The stock has a 50 day simple moving average of $0.84 and a 200 day simple moving average of $0.85.

Analyst Ratings Changes

Several brokerages have weighed in on KTTA. HC Wainwright initiated coverage on Pasithea Therapeutics in a report on Monday, December 8th. They issued a “buy” rating and a $3.00 price objective for the company. Zacks Research raised Pasithea Therapeutics to a “hold” rating in a report on Tuesday, December 9th. Weiss Ratings restated a “sell (e+)” rating on shares of Pasithea Therapeutics in a research report on Monday, December 29th. Finally, Wall Street Zen raised Pasithea Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, January 18th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Pasithea Therapeutics has an average rating of “Hold” and an average price target of $3.00.

Hedge Funds Weigh In On Pasithea Therapeutics

A number of hedge funds have recently modified their holdings of the business. Janus Henderson Group PLC bought a new stake in shares of Pasithea Therapeutics in the fourth quarter worth $2,720,000. Vivo Capital LLC bought a new position in Pasithea Therapeutics during the 4th quarter worth $2,709,000. Squadron Capital Management LLC bought a new position in Pasithea Therapeutics during the 4th quarter worth $2,709,000. Adage Capital Partners GP L.L.C. acquired a new position in Pasithea Therapeutics during the 4th quarter worth about $2,709,000. Finally, Persistent Asset Partners Ltd bought a new stake in shares of Pasithea Therapeutics in the 4th quarter valued at about $375,000. Institutional investors and hedge funds own 23.92% of the company’s stock.

Pasithea Therapeutics Company Profile

Pasithea Therapeutics, Inc (NASDAQ: KTTA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and eventual commercialization of engineered antibody therapeutics for immunological diseases. Leveraging a proprietary discovery engine that integrates advanced computational biology, high-throughput screening and structural analysis, the company aims to identify and generate novel therapeutic molecules that modulate key immune pathways.

The company’s pipeline consists of multiple preclinical and early clinical candidates targeting autoimmune and inflammatory disorders.